Working… Menu

Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00157976
Recruitment Status : Unknown
Verified November 2005 by Miravant Pharmaceuticals.
Recruitment status was:  Recruiting
First Posted : September 12, 2005
Last Update Posted : December 1, 2005
Information provided by:
Miravant Pharmaceuticals

Brief Summary:
The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).

Condition or disease Intervention/treatment Phase
Macular Degeneration Drug: Photrex (rostaporfin) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 660 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD
Study Start Date : September 2005

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Visual Acuity

Secondary Outcome Measures :
  1. Angiographic changes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients with age greater than or equal to 50 years with at least one subfoveal CNV membrane secondary to AMD that can be demonstrated by fluorescein angiography.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00157976

Layout table for location contacts
Contact: Miravant Pharmaceuticals 1-800-685-2959

Layout table for location information
Multiple Investigators Recruiting
Sofia, Bulgaria
Czech Republic
Multiple Investigators Recruiting
Brno-Bohunice, Olomouc, Praha, Czech Republic
Multiple Investigators Recruiting
Warsaw, Bydgoszcz, Lubin, Poland
Multiple Investigators Recruiting
Bucharest, Romania
Sponsors and Collaborators
Miravant Pharmaceuticals
Layout table for investigator information
Study Director: Wendy J. Snyder, PhD Miravant Pharmaceuticals

Layout table for additonal information Identifier: NCT00157976     History of Changes
Other Study ID Numbers: MRVT-920101-OPH005
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: December 1, 2005
Last Verified: November 2005
Keywords provided by Miravant Pharmaceuticals:
Macular Degeneration
Visual Acuity
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Tin etiopurpurin
Photosensitizing Agents
Dermatologic Agents